Previsão
O preço-alvo médio dos analistas é € 86,58 (+36,35%). A mediana é € 86,58 (+36,35%).
| Comprar |
10 |
| Manter |
2 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
RadNet beats Q2 forecasts and raises full-year guidance
RadNet reported adjusted EPS of $0.29 for Q2 2026 on revenue of $622.7m, both well above consensus estimates, and posted an adjusted EBITDA quarterly record of $99.7m. Total revenue rose 25% year over year, driven by stronger demand for advanced imaging and a 56.5% increase in digital-health revenue; ARR nearly doubled to $105.5m. The company raised its full-year targets for imaging revenue, adjusted EBITDA and free cash flow. The stock rose about 6% in after-hours trading, while management highlighted accelerated adoption of AI solutions and continued wage-pressure and integration risks. » Mais em de.investing.com
RadNet secures $250 million loan and lowers interest costs
RadNet has amended its existing credit agreement and taken on an additional $250 million loan, which is being combined with the existing facility (totaling $1.2087 billion) and matures on April 18, 2031. Quarterly principal payments will rise from $2.4 million to about $3.1 million. RadNet plans to use the funds for acquisitions, organic growth, healthcare partnerships and general corporate purposes. The interest rate has been cut by 0.25 percentage points (choice of Term SOFR plus 2.00% or an alternate base rate plus 1.00%), and the terms of the revolving credit line were also improved, strengthening the company’s financial flexibility with a cash position of $455 million as of March 31, 2026. » Mais em de.investing.com
DeepHealth (RadNet subsidiary) launches AI platform Reporting Pro for radiology reporting
DeepHealth, a wholly owned subsidiary of RadNet, has made Reporting Pro commercially available — an AI-powered platform for creating radiology reports that combines speech recognition, clinical AI findings, measurements, generative AI assessments, and quality assurance in a single workflow. The solution incorporates both FDA-cleared and CE-marked AI tools, can integrate with existing PACS/RIS systems, and supports all imaging modalities. RadNet is rolling out Reporting Pro across its own network, has secured initial external customers, and plans to expand into additional countries by the end of the year. » Mais em de.investing.com
Moody's cuts rating of RadNet's senior secured bank credit facilities after $200m loan
Moody’s downgraded RadNet’s senior secured bank credit facilities from Ba3 to B1; the Corporate Family Rating remains at B1 with a stable outlook. The downgrade follows the issuance of an additional $200 million senior loan to finance acquisitions and expansion, which raises pro forma leverage from about 4.5x to around 5.0x. Moody’s cites higher fixed costs and geographic concentration as pressure points, but highlights RadNet’s strong competitive position, revenue diversification and a pro forma liquidity position of more than $600 million, and expects leverage to decline over the next 12–18 months. » Mais em de.investing.com
RadNet beats revenue forecasts in Q1 2026, stock rises despite EPS miss
RadNet reported Q1 2026 revenue of $575.63 million versus $557.64 million expected (+3.23% surprise) with EPS of $-0.28 (forecast -$0.15). Revenue rose 22.1% year over year, adjusted EBITDA increased 36.3%, and days sales outstanding (DSO) were 29.5 days. The stock climbed 8.95% in premarket trading to $63.40 as investors reacted positively to revenue growth, digital health initiatives and acquisition contributions. RadNet maintains an upbeat outlook with FY 2026 guidance of $0.63 EPS and expected revenues of $2.45 billion. » Mais em de.investing.com
Dados financeiros
No último trimestre, RadNet registou receitas de € 563,49 mi e um ganho líquido de € 3,67 mi
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 563,49 mi | 26,47% |
| Ganho bruto | 75,81 mi | 22,74% |
| Ganho líquido | 3,67 mi | 20,57% |
| EBITDA | 84,05 mi | 27,39% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 5 bi |
Número de ações | 78,77 mi |
Máximo/mínimo de 52 semanas | € 78,23 - € 46,31 |
| Dividendos | Não |
Beta | 1,40 |
PER (PE Ratio) | -242,22 |
PEG (PEG Ratio) | 3,65 |
P/VC (PB Ratio) | 4,84 |
P/V (PS Ratio) | 2,30 |
Perfil da empresa
A RadNet, Inc., em conjunto com as suas subsidiárias, presta serviços de diagnóstico por imagem em regime ambulatório nos Estados Unidos. Os seus serviços incluem ressonância magnética, tomografia computorizada, tomografia por emissão de positrões, medicina nuclear, mamografia, ecografia, radiologia de diagnóstico, fluoroscopia e outros procedimentos relacionados, bem como serviços de imagiologia multimodal. A empresa também desenvolve e comercializa sistemas informatizados para a indústria de diagnóstico por imagem, incluindo sistemas de arquivo e comunicação de imagens (PACS) e serviços relacionados; e desenvolve e implementa suites de IA para melhorar a interpretação de imagens por radiologistas no domínio da mamografia, bem como soluções de IA para o cancro do pulmão e da próstata. Em 31 de dezembro de 2021, detinha e geria 347 centros no Arizona, na Califórnia, no Delaware, na Florida, no Maryland, em Nova Jersey e em Nova Iorque. A empresa foi fundada em 1981 e tem sede em Los Angeles, Califórnia.
| Nome | RadNet |
| CEO | Howard G. Berger |
| Sede | Los Angeles,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Cuidados de saúde: equipamentos e produtos |
| Entrada em bolsa | 10/12/2021 |
| Colaboradores | 9.060 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | RDNT |
Frankfurt | PQIA.F |
Düsseldorf | PQIA.DU |
SIX | PQIA.SW |